Lung Neoplasms

Oncology
7
Pipeline Programs
9
Companies
16
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
4
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 13 programs with unclassified modality

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
3 programs
1
2
AfatinibPhase 2Small Molecule1 trial
vargatef®Phase 21 trial
BIBH 1Phase 11 trial
Active Trials
NCT02199886Terminated6
NCT01466660Completed319Est. Apr 2019
NCT02531737Completed59Est. Sep 2020
Alliance Pharmaceuticals
2 programs
1
MetforminPhase 23 trials
Risk Stratification of Patients Using the Lung Cancer Biomarker Panel in ChinaN/A1 trial
Active Trials
NCT01928836Completed764Est. Jan 2015
NCT01717482Terminated6Est. May 2019
NCT01478308Withdrawn0Est. Oct 2011
+1 more trials
CT
1 program
1
anlotinib plus chemotherapyPhase 21 trial
Active Trials
NCT03589950UnknownEst. Aug 2021
Pfizer
PfizerNEW YORK, NY
2 programs
1
CP-547,632Phase 1/21 trial
Validation of Molecular Diagnostic Thecnologies for Lung Cancer Patients.N/A1 trial
Active Trials
NCT03220230Completed4,240Est. Oct 2018
NCT00074854Completed87Est. Mar 2005
Blueprint Medicines
Blueprint MedicinesMA - Cambridge
1 program
1
BLU-945Phase 11 trial
Active Trials
NCT04862780Terminated177Est. Oct 2024
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
3 programs
EBUS-TBNAN/A1 trial
Efficacy of EGFR TKIs in Patients With Rare EGFR-mutated NSCLCN/A1 trial
LUNG-ROLL: Treatment Patterns and Cost of Illness of Lung Cancer in CanadaN/A1 trial
Active Trials
NCT03017183Completed30Est. Jul 2017
NCT01775943Unknown90Est. Feb 2014
NCT07143110Recruiting60,000Est. Sep 2027
M&
Merck & Co.RAHWAY, NJ
1 program
Sensitivity of PDL-1-analysis From Pleural Effusion in Non-small Cell Lung CancerN/A1 trial
Active Trials
NCT02855281Completed50Est. Dec 2018
Mauna Kea Technologies
1 program
probe based laser endomicroscopyN/A1 trial
Active Trials
NCT01793246CompletedEst. Dec 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Alliance PharmaceuticalsMetformin
Chia Tai TianQing Pharmaceutical Groupanlotinib plus chemotherapy
Boehringer Ingelheimvargatef®
Alliance PharmaceuticalsMetformin
Boehringer IngelheimAfatinib
Alliance PharmaceuticalsMetformin
PfizerCP-547,632
Blueprint MedicinesBLU-945
Boehringer IngelheimBIBH 1
AstraZenecaLUNG-ROLL: Treatment Patterns and Cost of Illness of Lung Cancer in Canada
AstraZenecaEBUS-TBNA
Merck & Co.Sensitivity of PDL-1-analysis From Pleural Effusion in Non-small Cell Lung Cancer
PfizerValidation of Molecular Diagnostic Thecnologies for Lung Cancer Patients.
AstraZenecaEfficacy of EGFR TKIs in Patients With Rare EGFR-mutated NSCLC
Mauna Kea Technologiesprobe based laser endomicroscopy

Showing 15 of 16 trials with date data

Clinical Trials (16)

Total enrollment: 65,839 patients across 16 trials

NCT00391261Alliance PharmaceuticalsMetformin

An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.

Start: Jul 2006Est. completion: Oct 200711 patients
Phase 4Completed
NCT03589950Chia Tai TianQing Pharmaceutical Groupanlotinib plus chemotherapy

Anlotinib Plus Chemotherapy for Patients With Advanced Non-small Cell Lung Cancer

Start: Aug 2018Est. completion: Aug 2021
Phase 2Unknown
NCT02531737Boehringer Ingelheimvargatef®

Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer

Start: Sep 2015Est. completion: Sep 202059 patients
Phase 2Completed
NCT01717482Alliance PharmaceuticalsMetformin

Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer

Start: Oct 2012Est. completion: May 20196 patients
Phase 2Terminated
NCT01466660Boehringer IngelheimAfatinib

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Start: Dec 2011Est. completion: Apr 2019319 patients
Phase 2Completed
NCT01478308Alliance PharmaceuticalsMetformin

Metformin With Standard Taxotere and Prednisone in the Treatment of Castration Resistant Prostate Cancer

Start: Jun 2011Est. completion: Oct 20110
Phase 2Withdrawn
NCT00074854PfizerCP-547,632

A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy

Start: May 2002Est. completion: Mar 200587 patients
Phase 1/2Completed
NCT04862780Blueprint MedicinesBLU-945

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

Start: Jun 2021Est. completion: Oct 2024177 patients
Phase 1Terminated
NCT02199886Boehringer IngelheimBIBH 1

Dose-escalation Study of BIBH 1 in Patients With Non-small Cell Lung Cancer Scheduled for Surgical Resection

Start: Jul 19986 patients
Phase 1Terminated
NCT07143110AstraZenecaLUNG-ROLL: Treatment Patterns and Cost of Illness of Lung Cancer in Canada

LUNG-ROLL: Treatment Patterns and Cost of Illness of Lung Cancer in Canada

Start: Aug 2025Est. completion: Sep 202760,000 patients
N/ARecruiting
NCT03017183AstraZenecaEBUS-TBNA

Detection of Heterogeneity in Central Lung Cancer - EBUS-TBNA and ctDNA Analysis vs. Endobronchial Forceps Biopsy

Start: Jan 2017Est. completion: Jul 201730 patients
N/ACompleted
NCT02855281Merck & Co.Sensitivity of PDL-1-analysis From Pleural Effusion in Non-small Cell Lung Cancer

Sensitivity of PDL-1-analysis From Pleural Effusion in Non-small Cell Lung Cancer

Start: Oct 2016Est. completion: Dec 201850 patients
N/ACompleted
NCT03220230PfizerValidation of Molecular Diagnostic Thecnologies for Lung Cancer Patients.

Validation of Molecular Diagnostic Thecnologies for Lung Cancer Patients.

Start: Jul 2015Est. completion: Oct 20184,240 patients
N/ACompleted
NCT01775943AstraZenecaEfficacy of EGFR TKIs in Patients With Rare EGFR-mutated NSCLC

Efficacy of EGFR TKIs in Patients With Rare EGFR-mutated NSCLC

Start: Mar 2013Est. completion: Feb 201490 patients
N/AUnknown
NCT01793246Mauna Kea Technologiesprobe based laser endomicroscopy

Registry Trial to Determine pCLE Image Interpretation Criteria and Preliminary Accuracy in the Lung

Start: Feb 2013Est. completion: Dec 2016
N/ACompleted
NCT01928836Alliance PharmaceuticalsRisk Stratification of Patients Using the Lung Cancer Biomarker Panel in China

Risk Stratification of Patients Using the Lung Cancer Biomarker Panel in China

Start: Oct 2012Est. completion: Jan 2015764 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
2h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
2h ago

Office Administrator

SystImmune
2h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
3h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
3h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
3h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 65,839 patients
9 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)